PhysIQ Closes $8M Series B Financing
Summary
PhysIQ, a Chicago, IL-based developer of solutions that leverage artificial intelligence (AI) to empower digital health for ambulatory patient monitoring and clinical trial support, closed an $8m Series B financing.Led by Gary Conkright, CEO, Director and Founder, physIQ VitaLink collects continuous physiological patient data from wearable and implantable sensors and applies AI technology to transform this data into personalized patient insight.Healthcare providers, payers, pharmaceutical and medical device companies are leveraging the FDA-cleared personalized analytics to manage at-risk ambulatory patients while pharmaceutical and medical device manufacturers integrate VitaLink into their clinical trials in order to capitalize on new, “real world” data sets to validate the safety and efficacy of their products.The VitaLink end-to-end solution includes: – the physIQ software platform and AI analytics suite, – third-party wearable biosensors, – a mobile Android device for secure patient data transmission, and – a clinician user interface.As a data- and device-agnostic platform, it can accommodate any Bluetooth-enabled biosensor and has been engineered to be massively scalable and capable of continuously monitoring tens of thousands of patients at a time.